

Kristen Stevenson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11892161/publications.pdf>

Version: 2024-02-01

42
papers

6,356
citations

361413
20
h-index

289244
40
g-index

42
all docs

42
docs citations

42
times ranked

10828
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Effect of Point Mutations in Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2011, 364, 2496-2506.	27.0	1,444
2	Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia. <i>Cell</i> , 2013, 152, 714-726.	28.9	1,202
3	<i>SF3B1</i> and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2011, 365, 2497-2506.	27.0	1,021
4	TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. <i>Blood</i> , 2014, 124, 2705-2712.	1.4	486
5	A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2014, 123, 1293-1296.	1.4	345
6	Locally Disordered Methylation Forms the Basis of Intratumor Methylome Variation in Chronic Lymphocytic Leukemia. <i>Cancer Cell</i> , 2014, 26, 813-825.	16.8	323
7	Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 124, 453-462.	1.4	286
8	<i>SF3B1</i> -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. <i>Blood</i> , 2020, 136, 157-170.	1.4	195
9	Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2014, 5, 3469.	12.8	171
10	Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. <i>Blood</i> , 2008, 112, 4425-4431.	1.4	153
11	RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice. <i>Blood</i> , 2018, 132, 935-947.	1.4	87
12	Growth dynamics in naturally progressing chronic lymphocytic leukaemia. <i>Nature</i> , 2019, 570, 474-479.	27.8	86
13	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. <i>Blood</i> , 2015, 126, 907-907.	1.4	85
14	Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. <i>Journal of Clinical Investigation</i> , 2013, 123, 3756-3765.	8.2	69
15	Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. <i>American Journal of Hematology</i> , 2019, 94, 446-454.	4.1	56
16	Targeted inhibition of CD47-SIRP α requires Fc-Fc γ R interactions to maximize activity in T-cell lymphomas. <i>Blood</i> , 2019, 134, 1430-1440.	1.4	45
17	A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial. <i>Blood</i> , 2015, 126, 80-80.	1.4	38
18	A strategy to improve treatment-related mortality and abandonment of therapy for childhood ALL in a developing country reveals the impact of treatment delays. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1395-1402.	1.5	34

#	ARTICLE	IF	CITATIONS
19	Characterization of Oral Involvement in Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1717-1721.	2.0	33
20	Dietary intake and childhood leukemia: The Diet and Acute Lymphoblastic Leukemia Treatment (DALLT) cohort study. <i>Nutrition</i> , 2016, 32, 1103-1109.e1.	2.4	29
21	An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26871.	1.5	23
22	Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2010, 85, 967-971.	4.1	19
23	2-D network model simulations of miscible two-phase flow displacements in porous media: Effects of heterogeneity and viscosity. <i>Physica A: Statistical Mechanics and Its Applications</i> , 2006, 367, 7-24.	2.6	18
24	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Cancer Discovery</i> , 2021, 11, 1424-1439.	9.4	16
25	Fluctuations in dietary intake during treatment for childhood leukemia: A report from the DALLT cohort. <i>Clinical Nutrition</i> , 2019, 38, 2866-2874.	5.0	14
26	Protective Effects of Dietary Intake of Antioxidants and Treatment-Related Toxicity in Childhood Leukemia: A Report From the DALLT Cohort. <i>Journal of Clinical Oncology</i> , 2020, 38, 2151-2159.	1.6	13
27	Activation of <i>Notch</i> and <i>Myc</i> Signaling via B-cell-Restricted Depletion of <i>Dnmt3a</i> Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2021, 81, 6117-6130.	0.9	10
28	The MDM2 Inhibitor NVP-CGM097 Is Highly Active in a Randomized Preclinical Trial of B-Cell Acute Lymphoblastic Leukemia Patient Derived Xenografts. <i>Blood</i> , 2015, 126, 797-797.	1.4	9
29	Miscible, vertical network model 2-D simulations of two-phase flow displacements in porous media. <i>Physica A: Statistical Mechanics and Its Applications</i> , 2004, 343, 317-334.	2.6	7
30	Randomized Comparison of IV PEG and IM E. Coli Asparaginase in Children and Adolescents with Acute Lymphoblastic Leukemia: Results of the DFCI ALL Consortium Protocol 05-01. <i>Blood</i> , 2011, 118, 874-874.	1.4	6
31	Prospective Evaluation of FDG-PET Imaging of Treatment Response in Relapsed Follicular Lymphoma. <i>Blood</i> , 2007, 110, 2331-2331.	1.4	6
32	Genetic ancestry and skeletal toxicities among childhood acute lymphoblastic leukemia patients in the DFCI 05-001 cohort. <i>Blood Advances</i> , 2021, 5, 451-458.	5.2	5
33	Higher Incidence of Treatment-Related Toxicities in Non-Hispanic Patients Undergoing Therapy for Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia on Dana-Farber Cancer Institute ALL Consortium Protocol 05-001. <i>Blood</i> , 2015, 126, 248-248.	1.4	5
34	A Phase I/II Trial of Bortezomib, Tacrolimus and Methotrexate for Prophylaxis of Acute Graft Versus Host Disease after HLA Mismatched Reduced Intensity Transplantation. <i>Blood</i> , 2008, 112, 1158-1158.	1.4	4
35	Hyperglycemia during induction therapy for acute lymphoblastic leukemia is temporally linked to pegaspargase administration. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29505.	1.5	4
36	Phase Ib Trial of the mTOR Inhibitor Everolimus Given in Combination with Multiagent Chemotherapy in Relapsed Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 3765-3765.	1.4	3

#	ARTICLE	IF	CITATIONS
37	BRAF V600E and Pten deletion in mice produces a histiocytic disorder with features of Langerhans cell histiocytosis. PLoS ONE, 2019, 14, e0222400.	2.5	2
38	Ocular abnormalities at diagnosis and after the completion of treatment in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2022, 69, e29542.	1.5	2
39	Response to Helsby and Tingle. American Journal of Hematology, 2011, 86, 384-384.	4.1	1
40	Autologous Peripheral Blood Stem Cell Products from Patients with Hematologic Malignancies Have Increased Frequency of Regulatory T Cells (CD4+FoxP3+ Treg).. Blood, 2008, 112, 2310-2310.	1.4	1
41	Large-Scale CLL Genome Analysis Reveals Novel Cancer Genes, Including SF3B1. Blood, 2011, 118, 463-463.	1.4	0
42	Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center. Blood, 2015, 126, 1304-1304.	1.4	0